{"id":"W4386002127","doi":"10.1093/oncolo/oyad210","title":"Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type <i>RAS</i> Metastatic Colorectal Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Array BioPharma; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Panitumumab; Medicine; Rash; Colorectal cancer; Internal medicine; Adverse effect; Tolerability; Phases of clinical research; MEK inhibitor; Oncology; Epidermal growth factor receptor; EGFR inhibitors; KRAS; MAPK/ERK pathway; Gastroenterology; Cancer; Clinical trial; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004559343,0.0001902767,0.0006972597,0.00004938145,0.0003650768,0.000006388253,0.000164253,0.00003639479,0.00004868085],"category_scores_gemma":[0.000506034,0.00008279963,0.00009647638,0.0006293161,0.000456068,0.00002041204,0.0002323705,0.0001168036,0.000001381291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001708583,"about_ca_system_score_gemma":0.0003664633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007793744,"about_ca_topic_score_gemma":0.002375031,"domain_scores_codex":[0.9987098,0.0001240592,0.0004196383,0.0002453045,0.0002574614,0.0002437149],"domain_scores_gemma":[0.9981942,0.001068892,0.0002675254,0.0002647163,0.0001572269,0.00004748545],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4213139,0.04362602,0.03325189,0.001702505,0.01808314,0.0003068952,0.1034657,0.0007510297,0.07139134,0.0005403567,0.02282163,0.2827456],"study_design_scores_gemma":[0.2641659,0.2592918,0.3149711,0.0007509978,0.01480591,0.000129371,0.06803977,0.001806305,0.03051847,0.0003071716,0.04428215,0.0009311524],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937134,0.0005937608,0.0000021846,0.001421326,0.000343267,0.003313198,0.0001949287,0.00004024134,0.0003777255],"genre_scores_gemma":[0.9979817,0.0005825973,0.00003838705,0.0001093477,0.00006116774,0.0003449181,0.000009145057,0.00002013799,0.0008526228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2818144,"threshold_uncertainty_score":0.3376471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08035892614467251,"score_gpt":0.3976185822566396,"score_spread":0.3172596561119671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}